Annual report
2342.TEDINET S100R0CX
Period2022-04-01 → 2023-03-31
Filed2023-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥12.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥11.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥25m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥199m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥892m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥95m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥256m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥332m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥410m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥546m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥441m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥202m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥440m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥10.7bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥10.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥8.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.5bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.4bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥21m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥148m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥216m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥982m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥48m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥319m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥835m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥485m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥667m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥194m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-24.32 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.52 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.38 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.95 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥109.31 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥11.91 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥356.98 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥388.43 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥283.07 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥254.29 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥281.32 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 56.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.4% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 32.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 236 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 213 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 248 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 250 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 223 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥397m | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥365m | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥377m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥437m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥456m | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥85m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥78m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥73m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥76m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥32m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥62m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥32m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥100m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥104m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥180m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥298m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥38m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.0bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥7.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥4.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥796m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.4bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.5bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-6.17 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.3 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.14 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.27 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥158 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.27 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥6 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥394.96 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥406.51 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥252.79 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥242.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥261.36 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.5% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 48.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.9% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 16,999,141 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,358,141 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 25 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 26 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 27 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 59
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥559,000 |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥363,000 |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥4.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥210m |
| Drug Discovery Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥203m |
| Drug Discovery Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥106m |
| Drug Discovery Support Businessreportable segment | employees | at 2023-03-31 | 163 pure |
| Drug Discovery Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.2bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2023-03-31 | ¥3.1bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥21m |
| Investments And Consulting Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥176m |
| Investments And Consulting Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥18m |
| Investments And Consulting Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.2bn |
| Investments And Consulting Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.2bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1m |
| Investments And Consulting Businessreportable segment | segment assets | at 2023-03-31 | ¥3.3bn |
| Investments And Consulting Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥164m |
| TGBS Businessreportable segment | employees | at 2023-03-31 | 67 pure |
| —segment total | employees | at 2023-03-31 | 230 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥123m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥184m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥394,000 |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥447,000 |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥13m |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥600,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥14m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥5.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥210m |
| Drug Discovery Support Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥620m |
| Drug Discovery Support Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥139m |
| Drug Discovery Support Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥11m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2022-03-31 | ¥3.0bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| Investments And Consulting Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥16m |
| Investments And Consulting Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥12m |
| Investments And Consulting Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.8bn |
| Investments And Consulting Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.8bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3m |
| Investments And Consulting Businessreportable segment | segment assets | at 2022-03-31 | ¥2.4bn |
| Investments And Consulting Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥271m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥636m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥152m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥12.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥12.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥14m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,476
| Item | Context | Value | Unit |
|---|---|---|---|
| Redemption of bonds fin cf | Prior1YearDuration | -223140000 | JPY |
| Redemption of bonds fin cf | CurrentYearDuration | -14000000 | JPY |
| Increase decrease in short term loans payable fin cf | Prior1YearDuration | -410000000 | JPY |
| Increase decrease in short term loans payable fin cf | CurrentYearDuration | -220000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 220000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 1240000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -327943000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -386473000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -17472000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -17503000 | JPY |
| Payments for long term accounts payable other fin cf | Prior1YearDuration | -73940000 | JPY |
| Payments for long term accounts payable other fin cf | CurrentYearDuration | -16135000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -298599000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -52103000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -100906000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -1183198000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 484981000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 498000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 1993000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 1588371000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -1159074000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3030149000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4618521000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4618521000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 3459447000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 16 | |
| Notes receivable trade | Prior1YearInstant | 28944000 | JPY |
| Notes receivable trade | CurrentYearInstant | 41934000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 862219000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 1037823000 | JPY |
| Contract assets | Prior1YearInstant | 2951000 | JPY |
| Contract assets | CurrentYearInstant | 3698000 | JPY |
| Write downs of inventories | Prior1YearDuration | 3492000 | JPY |
| Write downs of inventories | CurrentYearDuration | 163154000 | JPY |
| Directors compensations sga | Prior1YearDuration | 193070000 | JPY |
| Directors compensations sga | CurrentYearDuration | 208073000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 467472000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 471201000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 76012000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 57958000 | JPY |
| Commission fee sga | Prior1YearDuration | 226056000 | JPY |
| Commission fee sga | CurrentYearDuration | 223138000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 40210000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 37804000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 4756682000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 7819286000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 12575968000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | 600000 | JPY |
| Revenues from external customers | Prior1YearDuration | 12576568000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |